Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

F. Saad; Egils Vjaters; N. D. Shore; D. Olmos; N. Xing; A. J. P. D. S. Gomes; A. C. A. Mota; P. Salman; M. Jievaltas; A. Ulys; M. Jakubovskis; E. Kopyltsov; W. Han; L. Nevalaita; I. Testa; M-A. Le Berre; I. Kuss; H. Kunhiparambath

doi:10.1016/j.annonc.2024.08.2311

Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

F. Saad, Egils Vjaters, N. D. Shore, D. Olmos, N. Xing, A. J. P. D. S. Gomes, A. C. A. Mota, P. Salman, M. Jievaltas, A. Ulys, M. Jakubovskis, E. Kopyltsov, W. Han, L. Nevalaita, I. Testa, M-A. Le Berre, I. Kuss, H. Kunhiparambath

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	LBA68
Pages (from-to)	1257-1258
Journal	Annals of Oncology
Volume	35
Issue number	Suppl.2
DOIs	https://doi.org/10.1016/j.annonc.2024.08.2311
Publication status	Published - Sept 2024
Externally published	Yes
Event	Annual Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, Spain Duration: 13 Sept 2024 → 17 Sept 2024

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2024.08.2311

Cite this

Saad, F., Vjaters, E., Shore, N. D., Olmos, D., Xing, N., Gomes, A. J. P. D. S., Mota, A. C. A., Salman, P., Jievaltas, M., Ulys, A., Jakubovskis, M., Kopyltsov, E., Han, W., Nevalaita, L., Testa, I., Le Berre, M.-A., Kuss, I., & Kunhiparambath, H. (2024). Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial. Annals of Oncology, 35(Suppl.2), 1257-1258. Article LBA68. https://doi.org/10.1016/j.annonc.2024.08.2311

@article{0817b18e2b8b4292a5e66920c350e1da,

title = "Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial",

author = "F. Saad and Egils Vjaters and Shore, \{N. D.\} and D. Olmos and N. Xing and Gomes, \{A. J. P. D. S.\} and Mota, \{A. C. A.\} and P. Salman and M. Jievaltas and A. Ulys and M. Jakubovskis and E. Kopyltsov and W. Han and L. Nevalaita and I. Testa and \{Le Berre\}, M-A. and I. Kuss and H. Kunhiparambath",

year = "2024",

month = sep,

doi = "10.1016/j.annonc.2024.08.2311",

language = "English",

volume = "35",

pages = "1257--1258",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "Suppl.2",

note = "Annual Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 13-09-2024 Through 17-09-2024",

}

Saad, F, Vjaters, E, Shore, ND, Olmos, D, Xing, N, Gomes, AJPDS, Mota, ACA, Salman, P, Jievaltas, M, Ulys, A, Jakubovskis, M, Kopyltsov, E, Han, W, Nevalaita, L, Testa, I, Le Berre, M-A, Kuss, I & Kunhiparambath, H 2024, 'Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial', Annals of Oncology, vol. 35, no. Suppl.2, LBA68, pp. 1257-1258. https://doi.org/10.1016/j.annonc.2024.08.2311

Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial. / Saad, F.; Vjaters, Egils; Shore, N. D. et al.
In: Annals of Oncology, Vol. 35, No. Suppl.2, LBA68, 09.2024, p. 1257-1258.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

AU - Saad, F.

AU - Vjaters, Egils

AU - Shore, N. D.

AU - Olmos, D.

AU - Xing, N.

AU - Gomes, A. J. P. D. S.

AU - Mota, A. C. A.

AU - Salman, P.

AU - Jievaltas, M.

AU - Ulys, A.

AU - Jakubovskis, M.

AU - Kopyltsov, E.

AU - Han, W.

AU - Nevalaita, L.

AU - Testa, I.

AU - Le Berre, M-A.

AU - Kuss, I.

AU - Kunhiparambath, H.

PY - 2024/9

Y1 - 2024/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:001326612903078&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2024.08.2311

DO - 10.1016/j.annonc.2024.08.2311

M3 - Meeting Abstract

SN - 0923-7534

VL - 35

SP - 1257

EP - 1258

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.2

M1 - LBA68

T2 - Annual Congress of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 13 September 2024 through 17 September 2024

ER -

Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this